190 related articles for article (PubMed ID: 26473193)
21. Identification of a PAX-FKHR gene expression signature that defines molecular classes and determines the prognosis of alveolar rhabdomyosarcomas.
Davicioni E; Finckenstein FG; Shahbazian V; Buckley JD; Triche TJ; Anderson MJ
Cancer Res; 2006 Jul; 66(14):6936-46. PubMed ID: 16849537
[TBL] [Abstract][Full Text] [Related]
22. Correlation between histology and PAX/FKHR fusion status in alveolar rhabdomyosarcoma: a report from the Children's Oncology Group.
Parham DM; Qualman SJ; Teot L; Barr FG; Morotti R; Sorensen PH; Triche TJ; Meyer WH;
Am J Surg Pathol; 2007 Jun; 31(6):895-901. PubMed ID: 17527077
[TBL] [Abstract][Full Text] [Related]
23. Investigation of PAX3/7-FKHR fusion genes and IGF2 gene expression in rhabdomyosarcoma tumors.
de Souza RR; Oliveira ID; Caran EM; Alves MT; Abib S; Toledo SR
Growth Horm IGF Res; 2012 Dec; 22(6):245-9. PubMed ID: 23079386
[TBL] [Abstract][Full Text] [Related]
24. Activation of the hedgehog pathway confers a poor prognosis in embryonal and fusion gene-negative alveolar rhabdomyosarcoma.
Zibat A; Missiaglia E; Rosenberger A; Pritchard-Jones K; Shipley J; Hahn H; Fulda S
Oncogene; 2010 Dec; 29(48):6323-30. PubMed ID: 20818440
[TBL] [Abstract][Full Text] [Related]
25. Rhabdomyosarcoma: value of myogenin expression analysis and molecular testing in diagnosing the alveolar subtype: an analysis of 109 paraffin-embedded specimens.
Hostein I; Andraud-Fregeville M; Guillou L; Terrier-Lacombe MJ; Deminière C; Ranchère D; Lussan C; Longavenne E; Bui NB; Delattre O; Coindre JM
Cancer; 2004 Dec; 101(12):2817-24. PubMed ID: 15536621
[TBL] [Abstract][Full Text] [Related]
26. Survival outcomes of patients with localized FOXO1 fusion-positive rhabdomyosarcoma treated on recent clinical trials: A report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group.
Heske CM; Chi YY; Venkatramani R; Li M; Arnold MA; Dasgupta R; Hiniker SM; Hawkins DS; Mascarenhas L
Cancer; 2021 Mar; 127(6):946-956. PubMed ID: 33216382
[TBL] [Abstract][Full Text] [Related]
27. Identification of target genes of PAX3-FOXO1 in alveolar rhabdomyosarcoma.
Ahn EH; Mercado GE; Laé M; Ladanyi M
Oncol Rep; 2013 Aug; 30(2):968-78. PubMed ID: 23733015
[TBL] [Abstract][Full Text] [Related]
28. OLIG2 is a novel immunohistochemical marker associated with the presence of PAX3/7-FOXO1 translocation in rhabdomyosarcomas.
Kaleta M; Wakulińska A; Karkucińska-Więckowska A; Dembowska-Bagińska B; Grajkowska W; Pronicki M; Łastowska M
Diagn Pathol; 2019 Sep; 14(1):103. PubMed ID: 31493794
[TBL] [Abstract][Full Text] [Related]
29. ALK expression in rhabdomyosarcomas: correlation with histologic subtype and fusion status.
Corao DA; Biegel JA; Coffin CM; Barr FG; Wainwright LM; Ernst LM; Choi JK; Zhang PJ; Pawel BR
Pediatr Dev Pathol; 2009; 12(4):275-83. PubMed ID: 18788887
[TBL] [Abstract][Full Text] [Related]
30. Molecular biology of rhabdomyosarcoma.
Gallego Melcón S; Sánchez de Toledo Codina J
Clin Transl Oncol; 2007 Jul; 9(7):415-9. PubMed ID: 17652054
[TBL] [Abstract][Full Text] [Related]
31. Fusion status in patients with lymph node-positive (N1) alveolar rhabdomyosarcoma is a powerful predictor of prognosis: Experience of the European Paediatric Soft Tissue Sarcoma Study Group (EpSSG).
Gallego S; Zanetti I; Orbach D; Ranchère D; Shipley J; Zin A; Bergeron C; de Salvo GL; Chisholm J; Ferrari A; Jenney M; Mandeville HC; Rogers T; Merks JHM; Mudry P; Glosli H; Milano GM; Ferman S; Bisogno G;
Cancer; 2018 Aug; 124(15):3201-3209. PubMed ID: 29797665
[TBL] [Abstract][Full Text] [Related]
32. Molecular cytogenetic analysis consistently identifies translocations involving chromosomes 1, 2 and 15 in five embryonal rhabdomyosarcoma cell lines and a PAX-FOXO1A fusion gene negative alveolar rhabdomyosarcoma cell line.
Roberts I; Gordon A; Wang R; Pritchard-Jones K; Shipley J; Coleman N
Cytogenet Cell Genet; 2001; 95(3-4):134-42. PubMed ID: 12063389
[TBL] [Abstract][Full Text] [Related]
33. PAX3-FKHR and PAX7-FKHR gene fusions are prognostic indicators in alveolar rhabdomyosarcoma: a report from the children's oncology group.
Sorensen PH; Lynch JC; Qualman SJ; Tirabosco R; Lim JF; Maurer HM; Bridge JA; Crist WM; Triche TJ; Barr FG
J Clin Oncol; 2002 Jun; 20(11):2672-9. PubMed ID: 12039929
[TBL] [Abstract][Full Text] [Related]
34. Detection and clinical significance of bone marrow involvement in patients with rhabdomyosarcoma.
Krsková L; Mrhalová M; Hilská I; Sumerauer D; Drahokoupilová E; Múdry P; Kodet R
Virchows Arch; 2010 May; 456(5):463-72. PubMed ID: 20405298
[TBL] [Abstract][Full Text] [Related]
35. Myogenin, AP2β, NOS-1, and HMGA2 are surrogate markers of fusion status in rhabdomyosarcoma: a report from the soft tissue sarcoma committee of the children's oncology group.
Rudzinski ER; Anderson JR; Lyden ER; Bridge JA; Barr FG; Gastier-Foster JM; Bachmeyer K; Skapek SX; Hawkins DS; Teot LA; Parham DM
Am J Surg Pathol; 2014 May; 38(5):654-9. PubMed ID: 24618610
[TBL] [Abstract][Full Text] [Related]
36. Fusion-negative alveolar rhabdomyosarcoma: modification of risk stratification is premature.
Anderson JR; Barr FG; Hawkins DS; Parham DM; Skapek SX; Triche TJ
J Clin Oncol; 2010 Oct; 28(29):e587-8; author reply e589-90. PubMed ID: 20697086
[No Abstract] [Full Text] [Related]
37. Genomic Classification and Clinical Outcome in Rhabdomyosarcoma: A Report From an International Consortium.
Shern JF; Selfe J; Izquierdo E; Patidar R; Chou HC; Song YK; Yohe ME; Sindiri S; Wei J; Wen X; Rudzinski ER; Barkauskas DA; Lo T; Hall D; Linardic CM; Hughes D; Jamal S; Jenney M; Chisholm J; Brown R; Jones K; Hicks B; Angelini P; George S; Chesler L; Hubank M; Kelsey A; Gatz SA; Skapek SX; Hawkins DS; Shipley JM; Khan J
J Clin Oncol; 2021 Sep; 39(26):2859-2871. PubMed ID: 34166060
[TBL] [Abstract][Full Text] [Related]
38. Hyper-activation of Notch3 amplifies the proliferative potential of rhabdomyosarcoma cells.
De Salvo M; Raimondi L; Vella S; Adesso L; Ciarapica R; Verginelli F; Pannuti A; Citti A; Boldrini R; Milano GM; Cacchione A; Ferrari A; Collini P; Rosolen A; Bisogno G; Alaggio R; Inserra A; Locatelli M; Stifani S; Screpanti I; Miele L; Locatelli F; Rota R
PLoS One; 2014; 9(5):e96238. PubMed ID: 24797362
[TBL] [Abstract][Full Text] [Related]
39. PAX3-FOXO1 drives miR-486-5p and represses miR-221 contributing to pathogenesis of alveolar rhabdomyosarcoma.
Hanna JA; Garcia MR; Lardennois A; Leavey PJ; Maglic D; Fagnan A; Go JC; Roach J; Wang YD; Finkelstein D; Hatley ME
Oncogene; 2018 Apr; 37(15):1991-2007. PubMed ID: 29367756
[TBL] [Abstract][Full Text] [Related]
40. Detection of the PAX3-FKHR fusion gene in paediatric rhabdomyosarcoma: a reproducible predictor of outcome?
Anderson J; Gordon T; McManus A; Mapp T; Gould S; Kelsey A; McDowell H; Pinkerton R; Shipley J; Pritchard-Jones K;
Br J Cancer; 2001 Sep; 85(6):831-5. PubMed ID: 11556833
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]